Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

Idecabtagene vicleucel (ide‐cel; bb2121) is a B‐cell maturation antigen–directed chimeric antigen receptor (CAR) T cell therapy approved for treatment of patients with heavily pretreated relapsed and refractory multiple myeloma. This analysis evaluated exposure–response (ER) relationships of ide‐cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Connarn, Jamie N., Witjes, Han, van Zutphen‐van Geffen, Marielle, de Greef, Rik, Campbell, Timothy B., Hege, Kristen, Zhou, Simon, Lamba, Manisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681434/
https://www.ncbi.nlm.nih.gov/pubmed/36794354
http://dx.doi.org/10.1002/psp4.12922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681434/
https://www.ncbi.nlm.nih.gov/pubmed/36794354
http://dx.doi.org/10.1002/psp4.12922

Ejemplares similares